Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Effects on Antioxidant Capacity and Hemodynamics in CABG Surgery
IRCT20250404065205N1Phase 3Completed
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine in coronary arteriosclerosis, sponsored by Rajaie Cardiovascular Medical and Research Center. Primary endpoints: Total antioxidant capacity and Hemodynamic variables. Started May 2025; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20250404065205N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250404065205N1.